Gene Expression Market to reach $8.2 Billion by 2030; Continuous advancements in high-throughput sequencing technologies, increasing investments in personalized medicine and the rising demand for precision oncology and biomarker discovery are fueling

The Gene Expression Market size is estimated to reach $8.2 Billion by 2030, growing at a CAGR of 8.6% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “Gene Expression Market – By Technology ( Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), DNA Macroarray and Others), By Consumable ( Reagents, DNA Chips, By Application ( Research, Drug Discovery, Diagnostics and Others) and By Geography - Opportunity Analysis & Industry Forecast, 2024-2030.

Advancements in genomic technologies, such as next-generation sequencing (NGS) and real-time PCR, are significantly improving the efficiency, accessibility and accuracy of gene expression analysis. Additionally, the rising demand for personalized medicine, which tailors treatments to individual genetic profiles is further fueling the growth of the gene expression analysis market.

In 2023, the North America region held the largest share of 40% in the Gene Expression Market, driven by significant investments in biomedical research and genomic technologies across the United States and Canada. The region benefits from a strong infrastructure for scientific innovation and an advanced healthcare system with governments, research institutions and private companies continuing to lead in the adoption of cutting-edge technologies for genetic analysis and personalized medicine. Howard Hughes Medical Institute's (HHMI) announced, in July 2024, a $300 million investment in 26 of the nation's leading scientists. These researchers are driving advancements in fields ranging from neuroscience to immunology and structural biology with a focus on pushing the boundaries of scientific understanding and applications in biomedicine. This level of funding reinforces the growing demand for gene expression analysis as researchers seek to decode complex biological systems and accelerate the development of new therapies. This combination of cutting-edge research funding and the growing focus on personalized treatments in North America continues to fuel the region's dominance in the gene expression market.

Advancements in genomic technologies are a key driver of growth in the gene expression analysis market. These innovations such as CRISPR-based gene editing and next-generation sequencing (NGS) are opening new possibilities for personalized medicine, genetic therapies, and disease prevention. As these technologies evolve, they enable researchers and clinicians to gain deeper insights into genetic profiles improving the accuracy and effectiveness of treatments for a wide range of diseases. In April 2024, Regeneron Pharmaceuticals and Mammoth Biosciences announced a partnership that leverages Mammoth Biosciences’ CRISPR-based ultracompact gene editing platform to develop in vivo therapies targeting tissues and cell types beyond the liver, an area traditionally dominated by gene editing therapies. With CRISPR-based platforms being used to make precise edits to the DNA of living organisms, this partnership is expected to accelerate the development of novel genetic therapies and further advance the field of genetic medicine. These breakthroughs in genomic technologies are transforming the landscape of drug development enhancing the demand for gene expression analysis as tools become more advanced in targeting specific genetic issues.

Rising demand for personalized medicine is a major driver of growth in the gene expression analysis market. As advancements in genomics continue, there is an increasing shift toward tailored healthcare solutions that are designed to address the unique genetic makeup of individual patients. Personalized medicine enables more precise treatments, improving efficacy and minimizing side effects by targeting the root causes of diseases at the genetic level. In November 2024 CE-Ventures revealed plans to host a groundbreaking symposium titled- The Microbiome and Genomics Revolution: Personalising Medicine for Health and Longevity in December 2024. The symposium will explore the intersection of the microbiome, genomics and personalized healthcare solutions, reflecting the increasing focus on creating tailored treatments to improve health outcomes and longevity. With healthcare spending in the Middle East projected to exceed $200 billion by 2025, the region is placing a strong emphasis on innovative solutions to tackle chronic diseases further fueling the demand for genetic testing and personalized medicine. This growing interest in personalized healthcare and genomic research underscores the need for advanced gene expression analysis tools to create more precise and effective treatments, ultimately driving the expansion of the market.

• In December 2024, Strand Life Sciences introduced CancerSpot, an innovative blood-based test for the early detection of multiple cancers. This test utilizes advanced methylation profiling technology, a globally recognized method, to detect tumor DNA fragments in the blood, offering a simple and non-invasive approach for cancer screening.

• In November 2024, Parse Biosciences announced that OMAPiX has been officially certified as the newest member of its Certified Service Provider (CSP) Program. Through this partnership, OMAPiX becomes part of an esteemed network of service laboratories that offer Parse's scalable single-cell technology to researchers across the globe.

• In August 2023, Thermo Fisher Scientific introduced a new chromosomal microarray aimed at enhancing productivity, efficiency and profitability in cytogenetic research labs, offering an industry-leading two-day turnaround time. The Applied Biosystems CytoScan HD Accel array provides valuable insights into chromosomal variants for a wide range of prenatal, postnatal, and oncology research applications. It analyzes the entire human genome and offers improved coverage of over 5,000 critical genome regions.

Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina Inc., Roche, Bio-Rad Laboratories, Agilent Technologies, Inc., Affymetrix, GE Healthcare, Perkinelmer, Inc., Oxford Gene Technology and others.

Gene Expression Market - Gene Expression Market size is estimated to reach $15.9 billion by 2026, growing at a CAGR of 9.9% during the forecast period 2021-2026. Increase in the demand for personalized medicine, growing demand for gene expression in clinical diagnostics, drug discovery and growing demand for polymerase chain reaction (PCR) and next generation sequencing (NGS) technologies are the factors that are set to drive the growth.

Flotation Reagents Market - The flotation reagent market size is estimated to reach US$6.8 billion by 2027 and is growing at a CAGR of around 5.7% from 2022 to 2027 owing to huge mining industry projects which involve metallurgy, mineral processing processes, increasing oil and gas construction projects will drive the flotation reagent industry .

Single-cell Genome Sequencing Market - The Single-cell Genome Sequencing size is estimated to reach $9 billion by 2030, growing at a CAGR of 16.2% during the forecast period 2023-2030. The rising cases of cancer worldwide Rapid development in sequencing technologies is also expected to drive the growth of this market during the forecast period.